The Use of Enzyme Therapy to Regulate the Metabolic and Phenotypic Consequences of Adenosine Deaminase Deficiency in Mice
Open Access
- 1 October 2000
- journal article
- Published by Elsevier
- Vol. 275 (41) , 32114-32121
- https://doi.org/10.1074/jbc.m005153200
Abstract
No abstract availableKeywords
This publication has 28 references indexed in Scilit:
- Adenosine Deaminase-deficient Mice Generated Using a Two-stage Genetic Engineering Strategy Exhibit a Combined ImmunodeficiencyJournal of Biological Chemistry, 1998
- Human severe combined immunodeficiency: Genetic, phenotypic, and functional diversity in one hundred eight infantsThe Journal of Pediatrics, 1997
- Induction of Apoptotic Program in Cell-Free Extracts: Requirement for dATP and Cytochrome cPublished by Elsevier ,1996
- Hepatic Dysfunction as a Complication of Adenosine Deaminase DeficiencyNew England Journal of Medicine, 1996
- PEG-ADA replacement therapy for adenosine deaminase deficiency: an update after 8.5 yearsClinical Immunology and Immunopathology, 1995
- Adenosine Receptor Subtypes: Characterization and Therapeutic RegulationAnnual Review of Pharmacology and Toxicology, 1995
- Effects of (R)‐deoxycoformycin (pentostatin) on intrauterine nucleoside catabolism and embryo viability in the pregnant mouseTeratology, 1992
- Treatment of Adenosine Deaminase Deficiency with Polyethylene Glycol–Modified Adenosine DeaminaseNew England Journal of Medicine, 1987
- Amelioration of Neurologic Abnormalities after Enzyme Replacement in Adenosine Deaminase DeficiencyNew England Journal of Medicine, 1980
- Deoxyadenosine metabolism and cytotoxicity in cultured mouse T lymphoma cells: a model for immunodeficiency diseaseCell, 1978